| DPX-Based Immunotherapy | Indication | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Sponsor | Collaborators |
|---|---|---|---|---|---|---|---|
| Product |
Title
DLBCL |
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
Sponsor
|
Collaborators
|
| Product |
Title
Ovarian Cancer |
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
Sponsor
|
Collaborators |
|
Product
Maveropepimut-S (MVP-S) |
Title
Bladder, Liver, MSI-H Tumors (Basket Trial) |
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
Sponsor
|
Collaborators
|
| Product |
Title
Breast Cancer |
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Sponsor |
Collaborators
|
|
Product
MVP-S and DPX-SurMAGE |
Title
Non-Muscle Invasive Bladder Cancer |
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
Sponsor
|
Collaborators
|
IMV owns or is the exclusive licensee of all DPX-based product candidates.
Our First DPX-enabled Asset: MVP-S
MVP-S is the clinical demonstration of DPX potential in solid and hematologic cancers
Our lead DPX-based immunotherapy, maveropepimut-S (MVP-S, previously named DPX-Survivac), administered alone or in combination with other agents, has shown robust, persistent immune responses to the cancer antigen survivin, along with durable clinical benefits in patients with hematologic or solid cancer. In these studies, more than 300 subjects have received at least one dose of MVP-S alone or in combination. The treatment was well-tolerated with only mild to moderate injection site reactions as the primary adverse event.
Translational analyses have suggested that both cellular and humoral survivin-specific immune responses are important for the anti-cancer efficacy driven by treatments with MVP-S. Recent preclinical research has shown the involvement of Natural Killer cells in the MVP-S mediated anti-cancer immune response.
About MVP-SOur Dual-targeted Immunotherapy: DPX-SurMAGE
Our proof of principle for dual antigen therapy
DPX-SurMAGE is a DPX-based dual-targeted immunotherapy that combines survivin and MAGE-A9 antigens. In preclinical studies, DPX-SurMAGE has demonstrated that the versatility of the DPX platform incites an immune response against cancer-antigens. A phase 1 clinical trial in patients with non-muscle invasive bladder cancer (NMIBC) is currently evaluating both MVP-S and DPX-SurMAGE in two separate cohorts.